Stallergenes   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Antony Hauts-de-Seine France (1962)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2002
NCT00410930
First Marketed Drug
2013
sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair)
First NDA Approval
2013
sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair)
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Stallergenes, SAS

Active Ingredients

Marketed Drugs (1)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (2013 NDA)

Drugs in Phase 3 Trials (4)

Key: Stallergenes (3) Acquired (1)

birch allergen (2 trials)

house dust mite allergen (7 trials)

short ragweed pollen allergen (4 trials)

timothy grass pollen allergen extract (Grastek) (7 trials)

Drugs in Phase 2 Trials (2)

Key: Stallergenes (1) Acquired (1)

cow milk (1 trial)

rbet v1-fv (3 trials)

Drugs in Phase 1 Trials (1)

Key: Stallergenes (0) Acquired (1)

pf-04236921 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 2)

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Hypersensitivity (Phase 3)

Rhinitis (Phase 3)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Rhinitis, Allergic, Seasonal (Phase 3)

Stress, Psychological (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 24
  • # of Trial APIs: 7